title: Altered in vitro spreading and cytoskeletal organization in human glioma cells by downregulation of urokinase receptor.
abstract: The interaction of urokinase-type plasminogen activator (uPA) with its cell-surface receptor (uPAR) is implicated in diverse biological processes such as cell migration, tissue remodeling, and tumor cell invasion. Recent studies indicated that uPAR can act as an extracellular matrix receptor during cell adhesion. Recently, we showed that transfection of the human glioma cell line SNB19 with antisense uPAR resulted in downregulation of uPAR at both the mRNA and protein levels. In this study, we used SNB19 to determine how the presence or absence of uPAR promotes cell spreading and associated changes in cell morphology. Microscopic analysis of cell spreading revealed that antisense uPAR-transfected cells were larger, remained round, and did not spread efficiently over extracellular matrix substrate type IV collagen and fibronectin, unlike parental SNB19 cells, which were smaller and spindle shaped. Biochemical studies showed that antisense uPAR-transfected cells, in addition to not spreading, exhibited increased expression of alpha 3 beta 1 integrin but not alpha 5 beta 1 integrin. However, we could not find a change in the expression of extracellular matrix components or altered growth rate in these cells. Furthermore, despite the increased alpha 3 beta 1 integrin expression, antisense uPAR-transfected cells failed to form an organized actin cytoskeleton when plated on type IV collagen or fibronectin, unlike parental SNB19 cells, which displayed an organized cytoskeleton. These findings show that the absence of uPAR in human glioma cells leads to morphological changes associated with decreased spreading and a disorganized cytoskeleton resulting in altered cell morphology, suggesting that coordinated expression of uPAR and integrin may be involved in spreading of antisense uPAR-transfected glioma cells.
authors.affiliation: Department of Neurosurgery, University of Texas M. D. Anderson Cancer Center, Houston 77030, USA.
authors.forename: S K
authors.initials: SK
authors.lastname: Chintala
authors.forename: S
authors.initials: S
authors.lastname: Mohanam
authors.forename: Y
authors.initials: Y
authors.lastname: Go
authors.forename: B
authors.initials: B
authors.lastname: Venkaiah
authors.forename: R
authors.initials: R
authors.lastname: Sawaya
authors.forename: Z L
authors.initials: ZL
authors.lastname: Gokaslan
authors.forename: J S
authors.initials: JS
authors.lastname: Rao
mesh_terms: D002448:Cell Adhesion; D002465:Cell Movement; D003599:Cytoskeleton / Q000648:ultrastructure*; D016373:DNA, Antisense; D015536:Down-Regulation; D016326:Extracellular Matrix Proteins; D005909:Glioblastoma / Q000503:physiopathology* / Q000648:ultrastructure; D006801:Humans; D011956:Receptors, Cell Surface / Q000096:biosynthesis*; D055293:Receptors, Urokinase Plasminogen Activator; D014162:Transfection; D014407:Tumor Cells, Cultured; D014568:Urokinase-Type Plasminogen Activator / Q000378:metabolism
chemical_list: D016373:DNA, Antisense; D016326:Extracellular Matrix Proteins; C524898:PLAUR protein, human; D011956:Receptors, Cell Surface; D055293:Receptors, Urokinase Plasminogen Activator; D014568:Urokinase-Type Plasminogen Activator